Device Trial Radar · NCT03927508
First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Mar 14, 2019
Primary completion
Dec 19, 2019
Study completion Jan 23, 2020
Sponsor
- Lead sponsor
- Thrombolex, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
Conditions
- Pulmonary Embolism
Interventions
r-tPADrug
Pulse spray and infusion
The Bashir™ Endovascular CatheterDevice
The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Number of Participants With Major Bleeding EventsTime frame: Within 72 hours of initiation of r-tPA administration.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Advent Health Orlando
Orlando, Florida
St Vincent Hospital and Health Care Center, Inc.
Indianapolis, Indiana
Columbia University Medical Center - Presbyterian - New York
New York, New York
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.